Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

To see complete record on, please visit this link

Id: NCT05594667

Organisation Name: Cybin Therapeutics Inc.

Overal Status: Not yet recruiting

Start Date: December 15, 2022

Last Update: October 26, 2022

Lead Sponsor: Cybin Therapeutics Inc.

Brief Summary: This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups:

Group 1: ≤ 1 year
Group 2: 1 to ≤ 5 years
Group 3: 5 to ≤ 10 years
Group 4: > 10 years

  • Depression
  • Major Depressive Disorder
  • Mild Depression
  • Moderate Depression
  • Depressive Disorder

Total execution time in seconds: 0.31548094749451